These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29500433)

  • 1. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.
    Crawford N; Salvucci M; Hellwig CT; Lincoln FA; Mooney RE; O'Connor CL; Prehn JH; Longley DB; Rehm M
    Cell Death Differ; 2018 Nov; 25(11):1952-1966. PubMed ID: 29500433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer.
    McCann C; Matveeva A; McAllister K; Van Schaeybroeck S; Sessler T; Fichtner M; Carberry S; Rehm M; Prehn JHM; Longley DB
    FEBS J; 2021 Sep; 288(18):5374-5388. PubMed ID: 33660894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism.
    Lincoln FA; Imig D; Boccellato C; Juric V; Noonan J; Kontermann RE; Allgöwer F; Murphy BM; Rehm M
    Cell Death Dis; 2018 Nov; 9(11):1112. PubMed ID: 30385739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
    Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
    Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
    Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
    J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
    Xie X; Lee J; Liu H; Pearson T; Lu AY; Tripathy D; Devi GR; Bartholomeusz C; Ueno NT
    Mol Cancer Ther; 2021 Feb; 20(2):296-306. PubMed ID: 33323457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB.
    Oliver Metzig M; Fuchs D; Tagscherer KE; Gröne HJ; Schirmacher P; Roth W
    Oncogene; 2016 Jun; 35(26):3399-409. PubMed ID: 26522725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
    Srivastava AK; Jaganathan S; Stephen L; Hollingshead MG; Layhee A; Damour E; Govindharajulu JP; Donohue J; Esposito D; Mapes JP; Kinders RJ; Takebe N; Tomaszewski JE; Kummar S; Doroshow JH; Parchment RE
    Clin Cancer Res; 2016 Feb; 22(4):1000-10. PubMed ID: 26446940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism.
    Vetma V; Guttà C; Peters N; Praetorius C; Hutt M; Seifert O; Meier F; Kontermann R; Kulms D; Rehm M
    Cell Death Differ; 2020 Aug; 27(8):2417-2432. PubMed ID: 32081986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
    Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S
    Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.
    McComb S; Aguadé-Gorgorió J; Harder L; Marovca B; Cario G; Eckert C; Schrappe M; Stanulla M; von Stackelberg A; Bourquin JP; Bornhauser BC
    Sci Transl Med; 2016 May; 8(339):339ra70. PubMed ID: 27194728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
    Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
    Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.
    Paschall AV; Zimmerman MA; Torres CM; Yang D; Chen MR; Li X; Bieberich E; Bai A; Bielawski J; Bielawska A; Liu K
    BMC Cancer; 2014 Jan; 14():24. PubMed ID: 24422988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
    Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.